$1.40
-0.05 (-3.45%)
Open$1.44
Previous Close$1.45
Day High$1.46
Day Low$1.39
52W High$2.62
52W Low$0.72
Volume—
Avg Volume779.4K
Market Cap228.29M
P/E Ratio1.23
EPS$1.67
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+2,485.7% upside
Current
$1.40
$1.40
Target
$36.20
$36.20
$24.75
$36.20 avg
$54.95
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 53.72M | 91.87M | 45.49M |
| Net Income | 214.01M | 329.42M | -11,017,037 |
| Profit Margin | 398.4% | 378.5% | -24.2% |
| EBITDA | -225,723,474 | -366,747,563 | -13,211,435 |
| Free Cash Flow | — | — | -11,236,120 |
| Rev Growth | -41.5% | -41.5% | +9.2% |
| Debt/Equity | 0.84 | 0.84 | 0.72 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |